Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. (PROF) is a commercial-stage medical device company that regularly issues news on its AI-powered, MRI-guided, incision-free therapies for tissue ablation. The company’s updates frequently center on its TULSA-PRO system and the TULSA Procedure™, which are used to treat prostate cancer and benign prostatic hyperplasia (BPH) using robotically controlled, transurethral ultrasound under real-time MRI guidance.
News coverage for Profound often highlights new clinical milestones, such as first commercial TULSA-PRO cases at major academic hospitals, expansion of TULSA-PRO programs at imaging suites, and recognition of clinical trial data comparing the TULSA Procedure to robotic radical prostatectomy. Releases also describe real-world experience across the prostate disease spectrum, including cancer-only, hybrid cancer and BPH cases, BPH-only patients, and salvage therapy for radio-recurrent localized prostate cancer.
Investors and clinicians following PROF can also expect announcements on regulatory and commercial developments. These include exclusive distribution and supply agreements for TULSA-PRO and Sonalleve in regions such as Canada, Saudi Arabia, Australia and New Zealand, as well as financing transactions like registered direct offerings and private placements used to support sales expansion, research and development, and working capital.
In addition, Profound’s news flow covers product enhancements such as the TULSA-AI® Volume Reduction module for BPH, new clinical data presented at medical meetings, and updates on the installed base and qualified sales pipeline for TULSA-PRO systems. This page aggregates these company-issued releases and related coverage, offering a single location to review the latest developments affecting Profound Medical’s technologies, commercial footprint and capital markets activity.
Profound Medical (NASDAQ:PROF) announced that its TULSA-PRO MRI-guided, incision-free prostate therapy will be featured in multiple presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto, April 11-15, 2026.
Highlights include five oral talks on April 12 and additional sessions on April 13 showcasing CAPTAIN trial data, systematic reviews, and automation advances in MRI-guided prostate ablation.
Profound Medical (NASDAQ:PROF) congratulated Texas Prostate and Dr. James Cochran for completing their 100th TULSA Procedure at Dallas Medical Center on March 27, 2026. Texas Prostate reported a 500% increase in TULSA volumes after shifting from private-pay to a Medicare collaboration, expanding patient access.
The TULSA Procedure uses the TULSA-PRO system with MRI-guided, robotic directional ultrasound and real-time thermography to ablate prostate tissue with precise temperature control.
Profound Medical (NASDAQ:PROF) reported that the randomized CAPTAIN trial met its prespecified primary safety endpoint: preservation of erectile function and urinary continence at 6 months favored the TULSA Procedure 50% vs robotic radical prostatectomy (RP) 24% (p<0.05, RR 2.1).
CAPTAIN enrolled 211 patients across 23 sites. Key benefits after TULSA included 84% pad-free continence, 56% erectile function, zero median blood loss, shorter hospital stay, fewer hospitalizations (0.7% vs 6.3%), and faster return to work. 12-month TULSA oncologic data are pending.
Profound Medical (NASDAQ:PROF) announced that the first clinical outcomes from the Level 1 post‑market CAPTAIN trial comparing the TULSA Procedure with robotic radical prostatectomy will be presented at EAU 2026 on March 13, 2026 at 9:40 a.m. EDT.
Profound will issue a follow-up press release and host an investor webinar at 11:30 a.m. EDT on March 13 where Dr. Laurence Klotz will review CAPTAIN data; management will also hold one‑on‑one meetings at the ROTH Conference March 22–24, 2026 in Dana Point, CA.
Profound Medical (NASDAQ:PROF) reported record Q4-2025 revenue of $6.0M, up 43% year-over-year and 13% sequentially, and full-year 2025 revenue of $16.1M. Installed base stood at 78 systems with a pipeline of 110 potential new systems and an expectation of ~120 installs by end-2026. The company closed equity financings totaling $42.45M in Dec 2025, ended the year with $59.7M cash, and reported a full-year net loss of $42.6M (GAAP). Notable operational milestones include CMS reimbursement at Urology APC Level 7, launch of TULSA-AI for BPH, and selected late-breaking CAPTAIN trial outcomes presentation in March 2026.
Profound Medical (NASDAQ:PROF) will release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and business developments. A live webcast and archived recording will be available in the company Investors section.
Profound Medical (NASDAQ:PROF) received INOVAIT’s 2025–2026 Mount Logan Award for the TULSA Procedure™ and its commercial milestones. Key highlights include treating the 4,000th TULSA patient, securing new U.S. Medicare reimbursement codes, regaining exclusive Canadian distribution rights, and expanding global access via partnerships and a North America direct sales team.
The TULSA-PRO® system uses robotically controlled directional ultrasound with real-time MRI thermography to heat prostate tissue precisely, aiming to minimize blood loss, hospital stays, and common surgery or radiation side effects.
Profound Medical (NASDAQ:PROF) announced that PRO FAMILIA Specialist Hospital in Rzeszów, Poland completed its 500th Sonalleve procedure on Feb 5, 2026, marking a commercial milestone for the incision-free, MRI-guided uterine therapy.
The company reports 10 Sonalleve devices currently operational across Europe, China and Southeast Asia, with over 4,000 women treated and approximately $10 million in research grants awarded in the past five years to support clinical studies.
Profound notes Sonalleve is mainly sold as a one-time capital purchase and is seeing growth internationally while U.S. commercialization focus remains on TULSA-PRO.
Profound Medical (NASDAQ:PROF) will participate in two investor events in February 2026: the Lake Street Life-Sciences Invitational on Feb 4–5 in Scottsdale, AZ, and the BTIG 13th Annual MedTech conference on Feb 10–11 in Snowbird, UT. No webcasts will be available due to event formats.
Profound Medical (NASDAQ:PROF) announced that Mount Sinai Hospital performed its first incision-free, MRI-guided TULSA Procedure for prostate disease on Jan 15, 2026, making Mount Sinai the first health system in the New York Metro Area to offer TULSA-PRO.
The robotically controlled ultrasound system heats tissue to a kill temperature of 55–57°C with real-time MRI thermography and autonomous temperature adjustment, enabling tailored ablation with no procedural blood loss, same-day discharge, and intent to minimize urinary incontinence and erectile dysfunction versus surgery or radiation.
Mount Sinai is ranked No. 6 nationally for Urology (2025–26), and hospital clinicians plan future studies and guideline work using TULSA-PRO.